Patent ID: 6130221
Filing Date: 2000-10-10
Classification: A61P,C07C,C07D

Abstract:
A composition for treating cerebral amyloidosis, comprising a pharmaceutically effective amount of:(i) a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to (a) prevent disruption, or (b) if disrupted, act on pre-disrupted DMS in such a way that the compound, when compared to controls:(1) reduces the mean volume of tissue occupied by disrupted DMS;(2) reduces the ratio of the number of inflammatory cells per DMS; or(3) increases the ratio of the number of macrophages containing disrupted DMS per DMS;when the compound is administered to a test animal that has received an injection of DMS, and(ii) a pharmaceutically acceptable vehicle,wherein the compound is represented by the following general Formula (I): ##STR34## wherein: R.sub.1 and R.sub.2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C2-C5 alkynyl, nitro, and halogen;R.sub.5 and R.sub.6 are independently selected from the group consisting of C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C2-C5 alkynyl, phenyl, benzyl, naphthyl, and anthracenyl;wherein each aromatic ring may be substituted by one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, and C1-C5 haloalkyl;m is an integer selected from the group consisting of 0, 1, 3, 4, and 5;n is 1; ora pharmaceutically acceptable salt of such compound.